Lataa...
First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib
Imatinib, a tyrosine kinase inhibitor (TKI) of BCR-ABL, was the standard first-line therapy for chronic myeloid leukemia (CML) for almost 10 years. Dasatinib and nilotinib, two newer drugs with higher potency than imatinib against BCR-ABL and activity against most imatinib-resistant BCR-ABL mutation...
Tallennettuna:
| Päätekijät: | , , |
|---|---|
| Aineistotyyppi: | Artigo |
| Kieli: | Inglês |
| Julkaistu: |
BioMed Central
2010
|
| Aiheet: | |
| Linkit: | https://ncbi.nlm.nih.gov/pmc/articles/PMC3000369/ https://ncbi.nlm.nih.gov/pubmed/21108851 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/1756-8722-3-47 |
| Tagit: |
Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!
|